Which hedge funds own DCPHEUR? DECIPHERA PHARMACEUTICALS IN, Q2 2026 13F holders
0 tracked hedge funds disclosed a position in DCPHEUR (DECIPHERA PHARMACEUTICALS IN) in their Q2 2026 13F filings, worth $0 in total.
- 0
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 0
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 0
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $0
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $0
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $0
- Combined value Sum of the holders' reported positions in the security.
- –
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Ownership over time
Who discovered DCPHEUR first? Beta
The run: Q2 2019 → Q2 2020, +430%
| Redmile Group, LLC high conviction | Q2 2018 | 1.4% | +10.4 pts |
| Eversept Partners, LP | Q1 2019 | 2.0% | +4.2 pts |
| Orbimed Advisors LLC | Q1 2019 | 1.3% | +2.7 pts |
| Cormorant Asset Management, LP | Q3 2019 | – | +2.2 pts |
| Apis Capital Advisors, LLC | Q3 2019 | – | – |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.